Doxydil Pharmaceuticals
Developing a non-narcotic pain treatment using a well-studied and understood molecule to relieve suffering associated with migraine headaches, arthritis, peripheral neuropathy, post-operative pain, periodontitis and other inflammation-related pain via a novel topical formulation.
A Common Sense Yet Revolutionary Approach for Treating Pain.
Tablet and capsule forms of doxycycline are widely prescribed as an antibiotic to treat pneumonia, venereal disease and other bacterial infections. It has been widely established that at sub-antimicrobial levels, doxycycline can instead be used as an immunomodulator (without disturbing healthy bacteria in the body or creating antibiotic resistance).
​
Doxydil is the first topical formulation of doxycycline hyclate and a base suspension. Case studies to date show that patients suffering from significant pain that had found little relief from conventional treatments experienced significant and rapid pain relief from the administration of Doxydil.
“People suffering from chronic pain should not have to risk addiction, kidney failure or other systemic consequences in order to find relief."
- Dr. Bruce Roseman, Chief Science Officer
1 US Patent Grant, 1 US Patent Pending
and Significant Case Study Support
Our work and associated patent portfolio is based on extensive observational data and quantifiable reductions in pain experienced by people suffering from migraine headache, chemotherapy-induced peripheral neuropathy, rheumatoid arthritis, post-operative recovery and other inflammation-related pain.
Dr. Gilla Kaplan
Special Advisor
Dr. Gilla Kaplan has had a distinguished career in medical research. She served as a member of Celgene's board of directors from 1998 until 2018.
Career highlights:
-
Bill and Melinda Gates Foundation - Director of the Global Health Program, Tuberculosis. International Scientific Advisory Committee.
-
New Jersey Medical School, The Public Health Research Institute Center, Professor of Medicine and Research Scientist.
-
Rockefeller University, Professor of Medicine and Research Scientist.
-
Recipient of multiple grants from the NIH-NIAID and other foundations.
-
Published over 200 original articles in peer-reviewed journals as well as monographs, book chapters, and review articles.
-
Howard Hughes Medical Institute - Scientific Advisory Board member
-
Chair of the Scientific Advisory Board of the Heiser Program for Research in Leprosy and Tuberculosis.
-
Chair of the Board of the Desmond Tutu HIV Foundation.
-
University of Tromsø (Norway) - MSc and PhD in Cellular Immunology.
Arnie Berman
Chief Business Officer
Arnie Berman has a wide-ranging background in the investment industry, as a Wall Street Technology Strategist, Macro-Sector Analyst, Director of Research and as CFO and COO of 2 start-up money management organizations. Analyzing, positioning and evangelizing for growth companies while helping private and public companies raise capital has been central to all of his career activities.
Realizing that the right combination of partnership expertise or capital would be necessary to scale up Dr. Roseman's treatment innovations beyond those fortunate few that had been treated in his medical practice, Arnie shifted career direction - with the objective of providing Doxydil with needed business know-how, messaging and outreach capabilities.
Over the course of his career, Arnie has been a frequent guest on CNBC and other financial television programs. He was regularly quoted in the Wall Street Journal, Forbes and other business publications. Arnie is a Chartered Financial Analyst – and a magna cum laude graduate of Brown University with an Sc.B. in Applied Mathematics / Economics.
Dr. Bruce Roseman
Inventor and Chief Science Officer
Dr. Bruce Roseman is a highly regarded pediatric neurologist in White Plains, NY and has been granted over 20 U.S. patents.
Career highlights:
-
Listed among Best Doctors in America by Castle Connelly and by Naifeh & Smith.
-
Co-author of articles in numerous medical journals including Lancet, Journal of Pediatrics, Pediatric Neuroscience, and Journal of the American Society of Child Psychiatry.
-
Peer reviewed presentations before the NIH, American Epilepsy Society, International Celiac Symposium, American Academy of Pediatrics, Child Neurology Society and other organizations.
-
Recipient of research grants from Columbia University and the Croll Foundation.
-
New York Medical Hospital – Chief of Pediatric Neurology
-
Columbia University – Professor of Speech & Pathology, Teacher’s College, Behavioral Sciences Dept.
-
Georgetown Medical School (M.D)., Johns Hopkins (Pediatric Residency). Columbia Presbyterian (Pediatric Neurology Fellowship).